on CureVac (NASDAQ:CVAC)
CureVac Reports Q3 and Nine-Month Financial Results for 2025
CureVac disclosed their third-quarter and nine-month financial outcomes for 2025 alongside business updates. The German Federal Cartel Office approved the planned merger with BioNTech, forecasting closure later in the year. BioNTech's exchange offer for CureVac shares began on October 21, 2025, ending December 3. Litigation with Pfizer/BioNTech over mRNA COVID-19 vaccines halted pending offer completion.
The European Medicines Agency cleared CureVac's CTA for the CVHNLC cancer candidate, and CVGBM Phase 1 proceeds as planned. CureVac's cash reserves stood at €416.1 million by September 30, 2025, continuing an expected cash runway through 2028.
Revenue fell significantly, namely due to the absence of a €480.4 million one-time GSK license agreement in 2024, while operating profit benefitted from a positive one-time U.S. Settlement Agreement effect. Net profit noted a decline, partly due to increased legal expenses related to the BioNTech merger.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CureVac news